Treatment of VAP due to Pseudomonas aeruginosa — When Not in Septic Shock, with Susceptibility Results Available

Clinical scenario

This protocol addresses ventilator-associated pneumonia caused by Pseudomonas aeruginosa in patients who are not in septic shock and are not at high risk for death (mortality risk below 15%), and for whom antibiotic susceptibility testing results are already available. In this lower-risk, culture-confirmed setting, antibiotic selection can be tailored to the specific isolate.

Treatment approach

When susceptibility results are in hand, definitive therapy is guided by the isolate's profile. Guidelines support a targeted monotherapy approach — a single susceptibility-matched antipseudomonal agent — rather than empiric combination therapy in this population. The complete antibiotic selection criteria, class-specific constraints, and course parameters are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciw353

For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy (strong recommendation, low-quality evidence).
High risk of death in the meta-regression analysis was defined as mortality risk >25%; low risk of death is defined as mortality risk <15%.
For patients with HAP/VAP due to P. aeruginosa, we recommend that the choice of an antibiotic for definitive (not empiric) therapy be based upon the results of antimicrobial susceptibility testing (strong recommendation, low-quality evidence).

View source ↗